drugset / Trial / NCT04976647
A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of HLX07 In Combination with HLX10 with or without Chemotherapy versus HLX10 with Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small Cell Lung Cancer.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria.
Timeline
- Start
- 2022-01-18
- Primary completion
- 2023-01-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PIMURUTAMAB | Monoclonal antibody | 1500 mg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Comparator | carboplaitin | Unknown | — | Intravenous |
| Comparator | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |